Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2005

01-08-2005 | Correspondence

Incorporation of uncertainty in health economic modelling studies

Author: Mark Nuijten

Published in: PharmacoEconomics | Issue 8/2005

Login to get access

Excerpt

The article in a recent issue of PharmacoEconomics by O’Hagan et al.[1] contains certain criticisms of my recent paper.[2] In the interests of open discussion and improved understanding, I am pleased to be given the opportunity by PharmacoEconomics to respond to the critique. …
Literature
1.
O’Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23 (6): 529–36PubMedCrossRef
2.
Nuijten MJC. Incorporation of statistical uncertainty in health economic modelling studies using second order Monte Carlo simulations. Pharmacoeconomics 2004; 22 (12): 759–69PubMedCrossRef
3.
Nuijten MJ, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003; 21 (13): 941–50PubMedCrossRef
4.
Nuijten MJ, Kosa J, Engelfriet P. Modeling the cost-effectiveness and budgetary impact for subpopulations. Eur J Health Econ 2003 Jun; 4 (2): 70–8PubMedCrossRef
5.
Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20 (12): 855–67PubMedCrossRef
6.
Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics 2002; 20 (9): 617–28PubMedCrossRef
7.
Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health 2001 Jul-Aug; 4 (4): 316–28PubMed
Metadata
Title
Incorporation of uncertainty in health economic modelling studies
Author
Mark Nuijten
Publication date
01-08-2005
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2005
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523080-00009

Other articles of this Issue 8/2005

PharmacoEconomics 8/2005 Go to the issue

Original Research Article

An economic evaluation of rizatriptan in the treatment of migraine

Practical Application

Real-world trials to answer real-world questions

Original Research Article

Cost of illness and its predictors for Parkinson’s disease in Germany

Review Article

Pharmaceutical policy regarding generic drugs in Belgium

Review Article

Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer

Original Research Article

Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK